Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acumen Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights",
"Corporate Presentation August 2023 1 Forward-Looking Statements 2 This"
07/20/2023 8-K Quarterly results
07/17/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/17/2023 8-K Quarterly results
06/08/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION"
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights",
"Corporate Presentation May 2023 1 Forward-Looking Statements 2 This"
04/27/2023 8-K Quarterly results
03/27/2023 8-K Investor presentation
Docs: "Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights",
"Corporate Presentation March 2023 1 Forward-Looking Statements 2 This"
03/15/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF"
02/01/2023 8-K Quarterly results
01/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/24/2022 8-K Quarterly results
09/12/2022 8-K Investor presentation
Docs: "Corporate Presentation, dated September 2022"
08/15/2022 8-K Quarterly results
08/01/2022 8-K Quarterly results
06/21/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/16/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights"
03/28/2022 8-K Quarterly results
01/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/15/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights"
11/10/2021 8-K Investor presentation
Docs: "Overview of ACU193 and INTERCEPT-AD Presentation, dated November 2021",
"Overview of ACU193 and INTERCEPT-AD Presentation, dated November 2021"
10/07/2021 8-K Quarterly results
08/31/2021 8-K Quarterly results
08/16/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights - Acumen's investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers to enter clinical trials - Initiated ACU-001, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's Disease - Closed initial public offering in July 2021, with aggregate net proceeds of $169 million Charlottesville, VA and Carmel, IN, August 16, 2021 - Acumen Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease , today reported finan..."
07/07/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy